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Ligand binding to proteins is not a static process, but
rather involves a number of complex dynamic transi-
tions. A flexible ligand can change conformation
upon binding its target. The conformation and
dynamics of a protein can change to facilitate ligand
binding. The conformation of the ligand, however, is
generally presumed to have one primary binding
mode, shifting the protein conformational ensemble
from one state to another. We report solution nuclear
magnetic resonance (NMR) studies that reveal per-
oxisome proliferator-activated receptor g (PPARg)
modulators can samplemultiple bindingmodesman-
ifesting in multiple receptor conformations in slow
conformational exchange. Our NMR, hydrogen/
deuterium exchange and docking studies reveal
that ligand-induced receptor stabilization and bind-
ing mode occupancy correlate with the graded
agonist response of the ligand. Our results suggest
that ligand and receptor dynamics affect the graded
transcriptional output of PPARg modulators.
INTRODUCTION
Activation of receptors by small molecule ligands is generally
described in terms of their ability to agonize (activate) or antag-
onize (block) receptor function. Nuclear receptors (NRs) are
multidomain ligand-dependent transcription factors for which
the molecular basis for ligand-mediated receptor activation is
often described by the ‘‘helix 12’’ or AF-2 (activation function-2)
conformational model (Heldring et al., 2007). This model pro-
poses a switch between an active and inactive conformation of
the receptor. Specifically, ligand binding induces stabilization
of the conformational mobility of the C-terminal helix, helix 12,
of the ligand binding domain (LBD), and helix 12 is referred to
as the master regulator of transcriptional activation of NRs.
This model has been viewed as a molecular roadmap for NR
drug discovery, detailing how to turn the receptor ‘‘on’’ or ‘‘off’’
via structure-function mechanisms (Moore et al., 2006). NuclearStructure 20, 139receptor ligands can induce a spectrum or graded response,
such as full agonism, partial agonism, antagonism, and inverse
agonism (Germain et al., 2006). For some NRs, such as the
estrogen receptors (ERs), the structural basis of the extremes
of these responses, full agonism or antagonism, is well de-
scribed by the helix 12 conformational model (Heldring et al.,
2007). Full agonist ligands position helix 12 in a conformation
favoring interaction with coactivator proteins. Antagonist ligands
block receptor activation either by promoting corepressor inter-
action or by positioning helix 12 to preclude coactivator binding.
Antagonists have also been shown to destabilize coreceptor
(in the case of homodimeric and heterodimeric receptors) and
other cofactor binding.
In contrast, the molecular mechanisms providing partial ago-
nism are poorly understood. Crystal structures of the apo
LBD of the NR peroxisome proliferator-activated receptor g
(PPARg), as well as co-crystal structures of PPARg LBD bound
to ligands with partial agonist activity all reveal helix 12 in the
canonical agonist position (Bruning et al., 2007), providing little
insight into the mechanism of action of full versus partial
agonists. In fact, all crystal structures of the PPARg LBD,
whether apo or bound to agonist or antagonist, have similar
backbone folds with little variation in helix 12 positioning (Brun-
ing et al., 2007; Chandra et al., 2008; Uppenberg et al., 1998).
Similar observations were made in the crystal structures of
full length PPARg in complex with its coreceptor retinoid X
receptor a (RXRa), DNA, ligands, and coactivator NR box
peptides (Chandra et al., 2008). Thus, whereas crystal struc-
tures of PPARg reveal atomic differences in the ligand contacts
within the receptor ligand-binding pocket (LBP), they provide no
insight into the graded activity of ligands. Based on these ob-
servations, we hypothesized that differences in PPARg ligand
binding modes and activity were largely controlled by receptor
dynamics (Berger et al., 2003; Bruning et al., 2007; Johnson
et al., 2000). Such dynamic effects are not easily resolved within
the scope of and time scales sampled by X-ray crystallography
(Bru¨nger, 1997). In support of this notion, hydrogen/deuterium
exchange (HDX) kinetic profiles implicate ligand subtype-
specific differences in receptor conformational dynamics in
the mechanism of graded PPARg agonism. NMR studies also
reveal that a selective PPARg modulator can alter dynamics
of the receptor in a manner that leads to selective gene expres-
sion profiles (Berger et al., 2003). However, the mechanism is–150, January 11, 2012 ª2012 Elsevier Ltd All rights reserved 139
Figure 1. Graded Response of PPARg Ligands
is Not Explained by Ligand-Receptor Crystal
Structures
(A) Chemical structures of rosiglitazone, MRL20 and
MRL24.
(B) Effect of ligands on PPARg transactivation in a
cotransfection assay in 293T cells using a Gal4-PPARg
expression vector and UAS-luciferase reporter (n = 4; error
bars, SEM).
(C) In vitro biochemical assay showing the ability of PPARg
ligands studied to block Cdk5-mediated phosphorylation
of PPARg.
(D) Cartoon diagram overlay of PPARg LBD crystal
structures bound to rosiglitazone (pink; PDB 2PRG),
MRL24 (blue; PDB 2Q5P), and MRL20 (orange; PDB
2Q59).
(E) The first principal component from the THESEUS
(Theobald and Wuttke, 2006, 2008) correlation matrix for
the ML superposition of the structures in (D) mapped onto
the PPARg LBD (PDB 1FM6). Regions colored similarly
(red or blue) are self-correlated, whereas regions colored
differently (red vs. blue) are anticorrelated.
(F) PPARg LBD structures bound to MRL24 (blue; PDB
2Q5P) andMRL20 (orange; PDB 2Q59) illustrate that these
structurally similar ligands bind in distinct ligand confor-
mations under the crystallization conditions (Bruning et al.,
2007).
Structure
Role of Dynamics in Graded PPARg Agonismmore complex as ligands not only regulate helix 12/AF-2-
mediated interactions with coregulators but also modulate
posttranslational modifications and other protein/coregulator
binding sites (Choi et al., 2011; Choi et al., 2010). For simplicity,
we refer to helix 12-mediated agonism as ‘‘classical agonism,’’
whereas other modes of modulation of specific NR target genes
are helix 12-independent and involve more global alterations
in receptor dynamics that alter specific posttranslational
modifications.
Here we applied solution nuclear magnetic resonance (NMR)
spectroscopy to further examine the mechanisms contributing
to graded PPARg agonism. Nuclear magnetic resonance is
sensitive to structure and dynamics on time scales, ranging
from ps-s and slower, and, in the slower cases, NMR is able to
observe multiple populations, even those that are lowly popu-
lated (Henzler-Wildman and Kern, 2007; Kleckner and Foster,
2011). In contrast, HDX and crystallography report on slower
time scales and, in the case of crystallography, the information
gleaned typically describes a low energy conformation averaged
over all molecules within the crystal lattice (Bru¨nger, 1997). From
a functional point of view, fast motions (ps-ns) indeed impact the
function of proteins. However, slower motions (ms-s and slower)
play an important role in many biological processes, including
enzyme catalysis and biomolecular interactions. We show that
PPARgmodulators with graded response profiles not only differ-
entially stabilize distinct regions of the receptor surface impor-
tant for function but also sample multiple binding modes within
the LBP of the receptor in slow conformational exchange. The140 Structure 20, 139–150, January 11, 2012 ª2012 Elsevier Ltd All rights reservedability of the ligands to sample multiple binding
modes propagates these dynamic effects to
the protein surfaces important for its function.
Our findings support the view that both ligandand protein dynamics contribute to the mechanism of action of
PPARg modulators.
RESULTS
Graded Response of PPARgModulators Is Not Apparent
from PPARg LBD Co-Crystal Structures
We focused on three potent PPARg modulators (Acton et al.,
2005) with low nM binding affinities that afford graded agonism
profiles (Figure 1A): (1) the prototypical full agonist rosiglitazone;
(2) MRL20, a full agonist that exhibits 60% transactivation
activity compared to rosiglitazone; and (3) MRL24, a partial ago-
nist that exhibits 25% activity compared to rosiglitazone. The
degree of transactivation in a cell-based receptor:promoter-
reporter co-transfection assay (Figure 1B) is concordant with
the ability of the ligands to induce interaction of a NR receptor
interaction domain (RID) from the steroid receptor coactivator-
1 (SRC1) protein with PPARg LBD as determined in a homoge-
neous time resolved fluorescence assay (Bruning et al., 2007).
More recently, we determined that the anti-diabetic efficacy
of PPARg modulators correlates with ligand-binding affinity
as well as their ability to block phosphorylation of PPARg at
Ser245, but not with the degree of classical agonism (Choi
et al., 2010; Ser273 in the PPARg2 sequence; PPARg1 num-
bering is used in structural studies and is thus used here). The
potency of blockage of Ser245 (Ser273:PPARg2) phosphoryla-
tion by ligands appears to be associated with the strength of
interaction of the ligand with the backbone amide at Ser342,
Structure
Role of Dynamics in Graded PPARg Agonismwith the carboxylic acid moiety of MRL24 being in closest prox-
imity to this amide. Consistent with our previous findings for
MRL24 and rosiglitazone (Choi et al., 2010), all three modulators
blocked Ser245 (Ser273:PPARg2) phosphorylation (Figure 1C),
and densitometry analysis suggests an efficacy rank order of
MRL24 > rosiglitazone > MRL20. However, crystal structures
of the PPARg LBD bound to these ligands reveal largely un-
changed backbone conformations (Figure 1D; Bruning et al.,
2007), though principal component analysis reveals some
propensity for structural differences originating from the LBP
(Figure 1E). Although MRL20 and MRL24 are regioisomers, and
thus nearly chemically equivalent, they flip binding mode within
the LBP of PPARg (Figure 1F; Bruning et al., 2007).
NMR Analysis of the PPARg LBD
NMR data collected on apo PPARg LBD reveals approximately
half of the expected NMR resonances (Figure 2A). The absence
of resonances here is likely due to conformational exchange on
an intermediate NMR time scale (kex zjDvj or the chemical
shift difference between states, which is on the order of
103/sec) (Johnson et al., 2000; Kleckner and Foster, 2011).
Backbone chemical shift assignments were obtained for the
PPARg LBD bound to the ligands rosiglitazone, MRL24 and
MRL20. Binding of the PPARg full agonist, rosiglitazone,
restores nearly all NMR resonances (Figure 2B), suggesting
that it fully stabilizes the receptor conformation on an interme-
diate time scale and is consistent with published NMR and
HDX studies of PPARg full agonists (Bruning et al., 2007;
Hamuro et al., 2006; Johnson et al., 2000; Lu et al., 2008). The
majority of residues for which NMR data is missing in the apo
form are located within the ligand-binding pocket and AF-2
coregulator-binding surface (Figure 2A), which comprises H3,
H4-5, and H12.
Compared to apo receptor, the partial agonist MRL24 and
near-full agonist MRL20 only partially stabilized the receptor
conformation on an intermediate time scale (Figures 2C and
2D, respectively). For MRL24, the missing resonances populate
the AF-2 surface, including H3, H4–H5, H7, H8, H10–H11, and
H12 (Figure 2C), and residues assigned in these regions show
very broad resonances, suggestive of conformational exchange
on the ms-ms time scale. These observations are in general
agreement with those observed for the PPARg partial agonist
nTZDpa (Berger et al., 2003). For MRL20, the regions stabilized
differ compared to the partial stabilization afforded by MRL24,
including missing resonances in b1, H20, and H3 and, to a lesser
degree, on H4-5, loop b3-b4, H7, H8, H10-11, and H12 (Fig-
ure 2D); resonances in the latter regions also show some degree
of line broadening. These observations are consistent with the
functional profile of these ligands in that MRL20 better stabilizes
the AF-2/helix 12 region through a ligand-receptor hydrogen
bond (Bruning et al., 2007) and displays a higher transactivation
profile (Figure 1B) and a higher degree of interaction with SRC-1
RID compared to MRL24 (Bruning et al., 2007). In contrast,
MRL24 better stabilizes the b sheet region in the LBP and
Ser245 (Ser273:PPARg2) surface and is more efficacious at
blocking Cdk5-mediated phosphorylation of Ser245 (Figure 1C).
Furthermore, our NMR data suggests that helix 12 is conforma-
tionally dynamic on an intermediate NMR time scale in the pres-
ence of MRL24 and, to a lesser degree, for MRL20, in contrast toStructure 20, 139the single conformation implied in ligand-receptor co-crystal
structures (Figure 1D; Bruning et al., 2007).
HDX Analysis of the PPARg LBD
For the studies reported here, we obtained HDX-MS data on a
high resolution mass spectrometer, offering improved sequence
coverage compared to our previous analysis (Bruning et al.,
2007). Compared to apo receptor, ligand binding induces stabi-
lization of several regions of the PPARg LBD (Table S1 available
online). Rosiglitazone protected hydrogen exchange in H2, H3,
H4-5, b2-b4, H6, L6-7, H7, H10-11, and H12 (Figure 2E). The
level of protection was robust for H3, H10-11, and H12 and
correlates well to residues with missing apo NMR resonances
that are observed in the presence of rosiglitazone. The level of
protection from hydrogen exchange induced by MRL24 and
MRL20 is also consistent with our NMR observations. In partic-
ular, MRL24 afforded robust protection of hydrogen exchange
for residues in the b sheet region and H6 (Figure 2F), which are
regions where NMR chemical shift assignments were obtained
(Figure 2C). Other regions that did not show robust alterations
of HDX kinetics in the presence of MRL24 had many missing
resonances in the NMR data, including H4-5, H10-11, and
H12. MRL20 induces moderate protection from hydrogen ex-
change for residues within H10-11 and H12 (Figure 2G), more
so than MRL24 but less than rosiglitazone. This is consistent
with the NMR data, where we observed NMR resonances for
some, but not all, residues within H10-11 and H12 in the pres-
ence of MRL20 (Figure 2D). Thus, the degree of ligand-induced
stabilization observed by NMR via the number of observed reso-
nances within H10-11 and H12, as well as the degree of ligand-
induced protection from hydrogen exchange, is correlated with
the graded response of PPARg agonists in a manner that is not
apparent from co-crystal structures.
Two Receptor Populations in Slow Conformational
Exchange
A number of residues within the PPARg LBD were observed with
two populations of NMR chemical shifts when bound to MRL24
and, to a lesser extent, MRL20 (Figure 3A). In contrast, the rosi-
glitazone-bound receptor primarily afforded only onemajor pop-
ulation of NMR chemical shifts (Figure S1). For example, Asp380
displays a single peak in the 3D TROSY-HNCO data for all forms
studied, apo or bound to ligand (Figure 3A). However, Met348,
Lys230, and others display two populations of NMR resonances
in the presence of MRL24, suggestive of slow conformational
exchange on a time scale of ms or slower. Similarly, when bound
toMRL20, several residues also display two populations of NMR
resonances, such as Lys230. In addition, the line shapes of other
residues display significant line broadening, including Met348
(Figure 3A), which is suggestive of conformational exchange on
the ms-ms time scale. Notably, the two populations of NMR reso-
nances are present through all NMR data used to assign back-
bone chemical shifts (Figure 3B) and when heterodimerized to
the RXRa LBD complexed with 9-cis retinoic acid (Figure 3C).
We attempted to use ZZ-exchange spectroscopy (EXSY) to
quantify the rate of slow exchange, which was limited because
of spectral overlap. No exchange peaks were observed for reso-
nances with resolved signals using relaxation delays, ranging
from 5 to 900 ms. This suggests the rate of slow exchange is–150, January 11, 2012 ª2012 Elsevier Ltd All rights reserved 141
Figure 2. NMR and HDX-MS Analysis Reveals Patterns Consistent with Graded Responses of PPARg Ligands
(A–D) Two-dimensional overlay of 3D TROSY-HNCO spectra and PPARg LBD structure (PDB 1FM6) colored by the presence (red) or lack of (white) assigned
NMR chemical shifts for (A) apo PPARg LBD, (B) PPARg LBD bound to rosiglitazone, (C) PPARg LBD bound to MRL24, and (D) PPARg LBD bound to MRL20.
Proline residues, which are not assigned using traditional NMR methods, are colored gray. Boxed regions indicate locations of resonances that are aliased/
folded. The backbone amides of the three most downfield shifted resonances for Leu401, Leu468, and Lys230 make strong hydrogen bonds to other side-chain
nuclei in crystal structures and correspond well to ligand activity profiles. Leu468 is part of helix 12 and is only fully stabilized when bound to rosiglitazone; a very
weak peak near the noise level is observed for Leu468 in some data in the presence of MRL20 but not for MRL24 (not shown). Lys230 displays two populations in
the presence of a graded/partial agonist.
(E–G) HDX-MS data for peptides listed in Table S1 in the presence of (E) rosiglitazone, (F) MRL24, and (G) MRL20 and mapped onto the PPARg LBD structure
(PDB 1FM6). Color key displays percentage reduction in HDX relative to apo PPARg LBD.
Structure
Role of Dynamics in Graded PPARg Agonismlikely on the order of seconds, either near the limit (near 0.2/s)
or outside of the slow exchange regime detectable by EXSY
(kex z0.2-100/s) (Kleckner and Foster, 2011). In addition, no
exchange peaks were observed in 15N-NOESY-TROSY data
(tmix = 120 ms). A similar slowly exchanging process, undetect-142 Structure 20, 139–150, January 11, 2012 ª2012 Elsevier Ltd All rable by EXSY, has been observed for the uncatalyzed cis/trans
proline isomerization in CypA (Bosco et al., 2002).
The average population fractions for a group of well-resolved
resonances are Paz0.7 and Pbz0.3 when bound to MRL24.
Residues with two populations when bound to MRL24 compriseights reserved
Figure 3. NMRData Implicates SlowConformational Exchange between TwoReceptor Conformations in theMechanismof Action of Graded
PPARg Modulators
(A) Regions of 3D TROSY-HNCO spectra for PPARg LBD in the apo form or bound to rosiglitazone, MRL24 andMRL20. NMR resonances for Asp380,Met348 and
Lys230 are fully stabilized when bound to rosiglitazone, but display varying degrees of two resonance populations when bound to MRL24 and MRL20.
(B and C) The two resonance populations were present in (B) data used for backbone assignments, including 3D TROSY-HNCA and TROSY-HN(CO)CA, and (C)
in 3D TROSY-HNCO data for [2H,13C,15N]-PPARg/[unlabeled]-RXRa LBD heterodimer bound to MRL24 and 9-cis-retinoic acid, respectively.
(D and E) PPARg LBD structure (PDB 1FM6) colored by residues with two chemical shift populations (red), line shapes suggesting two populations that have
significant overlap (pink), or with missing assignments likely from intermediate conformational exchange (blue) in the presence of MRL24. Proline residues are
colored gray. See also Figures S1 and S2.
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Role of Dynamics in Graded PPARg Agonismthe LBP and surrounding regions, including the b sheet surface,
H2, H3, H4-5, H6, H7, and H10-11 (Figure 3D). These residues
are contiguous with residues missing resonances likely due toStructure 20, 139intermediate conformation exchange and thus do not have
NMR chemical shift assignments. For MRL20, the two popula-
tions of resonances are less abundant compared to MRL24,–150, January 11, 2012 ª2012 Elsevier Ltd All rights reserved 143
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Role of Dynamics in Graded PPARg Agonismin particular in H2, H4-5, H6, and H10-11, some of which are
missing likely due to intermediate exchange but nonetheless
populate similar regions within the ligand-binding pocket (Fig-
ure 3E) with average population fractions for a group of well-
resolved resonances of Paz0.85 and Pbz0.15. Comparison of
NMR data for the PPARg LBD bound to MRL24 and MRL20
versus apo receptor (Figures 2A, 2C, 2D, and 3A) suggests
that the two populations of NMR chemical shifts observed in
the presence of MRL24 and MRL20 are not a consequence of
sampling apo and holo (ligand-bound) receptor states but are
rather two distinct ligand-bound conformations. This is particu-
larly notable for Lys230, which displays a different amide proton
chemical shift in the apo form compared to the two populations
observed for receptor-bound MRL24 and MRL20. These obser-
vations are supported by circular dichroism thermal melt anal-
ysis, which reveals that our samples are fully saturated under
our experimental conditions and confirms a 1:1 ligand-receptor
stoichiometry (Figure S2).
Multiple Ligand Binding Modes for MRL20 and MRL24
Residues displaying two populations of NMR chemical shifts
when bound to MRL24 or MRL20 primarily map to the LBP of
the PPARg (Figures 3D and 3E). We posited that slow conforma-
tional exchange between different ligand conformations could
be the origin of the two receptor populations. To investigate
this hypothesis, we used 1H and 19F ligand-observed NMR tech-
niques to directly monitor receptor-bound MRL20 and MRL24.
For the 19F NMR studies, there is one CF3 group in the re-
gioisomers MRL20 and MRL24, giving rise to one 19F NMR
peak (Figure 4A). When bound to the PPARg LBD, MRL20 (Fig-
ure 4B) shows several peaks in the 19F NMR data, some of which
are low intensity signals. These data suggest a primary chemical
shift environment (a primary conformation) for the CF3 group
(d = 55.1 ppm) and up to four minor chemical shift environ-
ments (d = 56.4, 57.4, 58.5, and 59.6 ppm; four minor
conformations). In contrast, when bound to the PPARg LBD,
MRL24 (Figure 4G) shows one primary peak in the 19F NMR
data, suggesting a single unique chemical environment for the
CF3 group in MRL24. These trends generally hold within the
context of the PPARg/RXRa heterodimer (Figures 4C and 4H),
although three of the four minor MRL20 19F chemical shift popu-
lations are not observed (Figure 4C), suggesting that heterodi-
merization with RXRa could influence the conformation of
MRL20 bound to PPARg. This can be rationalized as previous
NMR studies have shown that the binding of the RXRa hetero-
dimer partner to PPARg causes chemical shift perturbations
within H12 (Lu et al., 2008). Thus, because the acid group of
MRL20 makes a hydrogen bond contact with Y473 in H12, and
because the binding of RXRa influences the conformation of
H12, heterodimerzation could have an impact on the conforma-
tional dynamics of receptor-bound MRL20.
For the 1H NMR studies, 1D 1H spectra for MRL20 (Figure 4D)
and MRL24 (Figure 4I) were used to assign aliphatic proton
resonances (1–4 ppm; inset structures), which are better
resolved and fewer in number compared to the aromatic region
(6–8 ppm) after considering peaks arising from the buffer and
bulk water (Figure S3). When bound to the PPARg LBD,
MRL20 (Figure 4E) shows a large signal likely corresponding to
the methyl near carboxylic acid group (group 1 in the inset).144 Structure 20, 139–150, January 11, 2012 ª2012 Elsevier Ltd All rThere are three other peaks that likely correspond to the remain-
ing aliphatic signals (groups 2–4, marked with B); however,
several minor populations are observed. When considered with
the MRL20 19F NMR data (Figures 4A–4C), the data suggest
a primary conformation of MRL20 when bound to PPARg, as
well as several other chemical states (conformations) that are
lowly populated. However, the methyl group near the carboxylic
acid (group 1 in the inset), which associates near helix 12 in the
PPARg LBP (ligand-binding pocket), likely exists in one unique
chemical environment because of the nature of the dynamics
(vide infra); this is further described in Figure S4.
MRL24 (Figure 4I) shows two populations of 1H resonances
when bound to the PPARg LBD (Figure 4J). For the more easily
resolved aliphatic groups (Figure S3), the largest chemical shift
change is observed for the methyl near carboxylic acid group
(group 1 in the inset; Dd = 0.2 ppm), followed by the methylether
group (group 3; Dd = 0.09 ppm), methylene group (group 4;
Dd = 0.07) and 2-methylindole group (group 2; Dd = 0.05 ppm;
resonances are broader and less intense compared to the
others). When considered with the MRL24 19F NMR data (Fig-
ures 4F–4H), the data suggest that the aliphatic groups of
MRL24, which comprise two of the three ligand side chains,
sample two conformations. However, the CF3 group of MRL24,
which associates near helix 12 in the PPARg LBP on the third
ligand side chain, exists in one unique chemical environment
(conformation); this is further described in Figure S4. For each
of the four observable MRL24 protons in this aliphatic region
(Figures 4I and 4J; between 1–4 ppm), two peaks are observed
suggesting two primary ligand conformations in slow exchange
with average population fractions of Paz0.6 and Pbz0.4.
When considered with structures of the PPARg LBD
co-crystalized with these ligands (Bruning et al., 2007), the
receptor-bound ligand-detected NMR data reveals mechanistic
insight into the binding mode dynamics of the ligand (Figure 5A;
Figure S4). NMR resonances originating from the ligand side
chain near helix 12 within the LBP give rise to one NMR chemical
shift population (Figure 4; Figure S4). In contrast, NMR reso-
nances for the ligand side chains that associate within the LBP
near the b sheet, which is larger in volume compared to the
region near helix 12 (Sheu et al., 2005), display multiple popula-
tions (Figure 4; Figure S4). A model describing the dynamics of
receptor-bound MRL24 consistent with our NMR observations
would suggest that the ligand flips its binding mode around an
axis of rotation positioned parallel to the 2-methylindole and
CF3 groups. These groups display the smallest chemical shift
change among all MRL24 aliphatic groups, whereas the methyl
near carboxylic acid group and methylether group at the ends
of two ligand side chains display the largest chemical shift
changes.
Molecular Docking Reveals the Propensity for Multiple
Ligand-Binding Modes
To provide additional insight into the ability of MRL20 and
MRL24 to adopt multiple binding modes, we performed molec-
ular docking simulations using the program AutoDock Vina (Trott
and Olson, 2010). Analysis of the top five binding models for the
docking of MRL20 revealed one significant primary binding
mode with 91% occupancy (Figure 5B), according to the
canonical Boltzmann distribution at the temperature used inights reserved
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Figure 4. Receptor-Bound Ligand-Observe NMR Data Reveals Multiple Binding Modes for Graded PPARg Modulators
Ligand-observe 1D NMR data for MRL20 (A–E) and MRL24 (F–J), including 19F (A–C, F–H) and 1H (D, E, I, J) NMR data. 19F NMR data for MRL20 reveals that the
single CF3 group (A) displays multiple populations when bound to PPARg (B) and the PPARg/RXRa heterodimer (C), including one primary state and one-to-
several lowly populated states. 1H NMR data for MRL20 also reveals the aromatic and aliphatic groups (D) display a similar profile when bound to PPARg (E).
19F NMR data for the single CF3 group of MRL24 (F) reveals a single resonance population when bound to PPARg (G) or the PPARg/RXRa heterodimer (H).
1H NMR data for MRL24 reveals that the aromatic and aliphatic NMR resonances (I) are in two populations when bound to PPARg (J). Buffer signals are marked
with an asterisk in (D, E, I, J); primary MRL20 signals are marked with open circles in (E); four groups of two MRL24 populations are marked with solid black
brackets in (J). Figure S3 shows a zoomed in view of the aliphatic region for MRL24 in (J).
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Figure 5. Model of MRL20 and MRL24 Ligand Dynamics within the Ligand-Binding Pocket and Corroboration via Ligand Molecular Docking
(A) The ligand-observe NMR data suggest that the acid and nearby methyl groups of MRL20 and the CF3 group of MRL24 bind in the same smaller pocket within
the PPARg LBP. In contrast, the region of the LBP, in which the other ligand side chains associate, constitutes the largest cavity within the LBP, and NMR
resonances corresponding to the ligand atoms in this region display multiple populations. This suggests that the ligands sample multiple conformations/binding
modes in this region of the LBP and is supported by protein NMR studies indicating multiple receptor conformations (Figure 3).
(B–C) Average predicted binding energies and% ligand occupancy, according to the canonical Boltzmann distribution from the molecular docking of MRL20 (B)
and MRL24 (C). Data for the primary and secondary modes are colored blue and pink, respectively.
(D–E) Primary (blue) and secondary (pink) binding modes obtained in the molecular docking results for MRL20 (D) and MRL24 (E). Primary binding modes (blue)
closely match the binding mode captured in PPARg crystal structures (Bruning et al., 2007), whereas the secondary binding modes (pink) display a ligand
orientation flipped 180 relative to the primary orientation in a manner concordant with our NMR data (A; Figure S4).
Structure
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modes were reported, including a secondary binding mode
with 6% occupancy and three additional binding modes with
occupancy values around or less than 1%. For MRL24, analysis
of the top five binding modes (Figure 5C) revealed a primary
binding mode with 62% occupancy and a secondary binding
mode with 31% occupancy, whereas the remaining binding
modes had occupancy values of 2% or less. For both ligands,
the primary binding mode (Figures 5D and 5E; blue) closely
resembles the binding mode captured in PPARg crystal struc-
tures (Bruning et al., 2007). The secondary binding mode (Fig-
ures 5D and 5E; pink) displays a ligand orientation flipped
180 in a manner concordant with our NMR data (Figure S4)
around an axis of rotation positioned parallel the ligand side
chain associated near H12 within a smaller region of the LBP
(Figure 5A). For MRL24, the axis of rotation is approximately
parallel to the 2-methylindole and CF3 groups. For both ligands,
the remaining three binding modes displayed the ligand associ-
ating near the LBP entry/exit site (Figure 5A). None of the docked
binding modes predicted for MRL20 correspond to the crystal-146 Structure 20, 139–150, January 11, 2012 ª2012 Elsevier Ltd All rlized MRL24 binding mode and vice versa. Boltzmann distribu-
tion analysis of the energy separation between the primary/
crystal structure orientation, the secondary (flipped) binding
mode and other modes indicates that the flipped mode could
be significantly populated for both ligands, with MRL24 occu-
pying the flipped state to a larger degree than MRL20 (Figures
5B and 5C). As schematically detailed in Figure S4 and dis-
cussed previously, these docking results agree with our NMR
observations and are consistent with the topology of the PPARg
LBP. Namely, the portion of the ligand that flips binding mode
orientation in the molecular docking is located within a larger
pocket of the LBP, and atoms of the ligand within this region of
the pocket display multiple populations in the NMR data.
DISCUSSION
Much of what is known about NR structure-function relation-
ships has been derived from hundreds of X-ray crystallography
studies, which have captured static conformational ‘‘snap-
shots’’ of many ligand-receptor complexes. However, biologicalights reserved
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throughout a hierarchy of motional time scales, which plays an
important role in biological function. The concept of structural
dynamics in the NR field has been derived primarily from the
structural plasticity of H12 in the receptor LBD switching
between an ‘‘on’’ (agonist) and ‘‘off’’ (antagonist) conformation
in ligand-receptor co-crystal structures. More recently, HDX
studies have revealed that the receptor dynamic profiles of
some NR-ligand complexes correlate with the pharmacological
phenotype of the ligand in a manner that could not be inferred
from static crystal structures (Bruning et al., 2007; Dai et al.,
2008, 2009; Zhang et al., 2010). However, one key observation
lacking from these studies relates to the dynamics of ligand
binding, particularly the ability to bind in different binding modes
and the effect on receptor conformation. Although crystallog-
raphy provides high-resolution atomic insight into the molecular
details of NR ligand-receptor interactions and HDX is sensitive to
detecting ligand-induced changes in receptor dynamics, these
techniques are not suitable for observing multiple conforma-
tional populations in solution. Here, our solution NMR studies
provide, to our knowledge, the first insight describing a potential
role for both ligand and receptor dynamics in the mechanism of
action of graded PPARg modulators.
Our data suggest that the degree of partial agonism exhibited
by MRL20 and MRL24 is associated with (1) the presence of two
receptor populations in slow conformational exchange; (2) the
degree of receptor intermediate conformational exchange within
the LBP and AF-2 region; (3) the degree of receptor stabilization
observed by NMR and HDX; and (4) the ability of the ligand to
sample multiple binding modes and the relative binding mode
occupancy. It is well accepted that the ability of a ligand to
interact with H12 via a hydrogen bond with Tyr473 plays an
important role in the stabilization of receptor conformation and
transcriptional agonism. Our studies implicate a role for interme-
diate time scale dynamics in the H12/AF-2 surface as a likely
origin for reduced transactivation response. This type of general
phenomenon, in which the dynamics of a protein negatively
affects its function, has been previously described as ‘‘dynamic
dysfunction’’ (Mauldin et al., 2009; Peng, 2009). In the case of
MRL20 and MRL24, which are less efficacious agonists com-
pared to rosiglitazone, sampling more than one ligand binding
mode allosterically propagates a conformational disorder to
surfaces of the receptor that are important for function, con-
tributing to their reduced degree of agonism, while indepen-
dently contributing to their ability to stabilize the Ser245
(Ser273:PPARg2) phosphorylation surface.
Our ligand-observe NMR data suggest that MRL20 prefers
one conformation and samples several other lowly populated
conformations. On the other hand, MRL24 samples two primary
conformations with relative populations of 60% and 40%.
This can be structurally rationalized by the observation that the
MRL24 acid group forms a hydrogen bond with Ser342 on b3
within the large cavity of the PPARg LBP. The formation of this
hydrogen bond may lock the ligand into one of these two
preferred conformations and slow the conformational exchange
of MRL24 to the point in which two significant populations are
observed. In contrast, although MRL20 may prefer one binding
mode, it samples several other binding modes at lower occu-
pancy, perhaps as it does not form a hydrogen bond withStructure 20, 139Ser342. These observations and relative populations are corrob-
orated by molecular docking studies on MRL20 and MRL24,
which reveal that these ligands can flip binding mode orientation
in the large pocket within the LBP that displays ligand-specific
differences in receptor intermediate and slow time scale
dynamics. Two different interpretations of our ligand-observe
NMR data would suggest that either the ligand rotates, while
bound in the pocket, or binds in two different orientations as
a result of ligand on-off exchange. In terms of the latter interpre-
tation, the slow rate of exchange observed is consistent with the
low Kd of these ligands. The ability of MRL20 and MRL24 to
sample multiple binding modes would certainly impact the
dynamics of the receptor, which is apparent in the relative re-
ceptor populations observed in our NMR studies. When con-
sidered with graded transactivation profiles and differences in
efficacy for blocking Ser245 phosphorylation, the data suggest
that the dynamics of the ligand and receptor would both affect
function. One caveat to the docking results is that, because
the bonds are rotatable during the in silico docking, programs,
such as AutoDock Vina and others, can have difficultly finding
a ‘‘correct’’ bound conformation, leading to artifactual results,
such as 180 flipped binding modes (Trott and Olson, 2010).
However, our docking results (Figures 5B–5E) are supported
by our NMR results (Figures 3 and 4): (1) in terms of the ability
to sample multiple binding modes; (2) the relative populations
of the bindingmodes (% ligand occupancy in the docking versus
ligandPa andPb in theNMR studies); and (3) chemical shift differ-
ences of the functional groups of MRL24 that suggest two
bindingmodes rotating about an axis of rotation that would result
in a 180 flip. Our results perhaps challenge the notion that there
could be one ‘‘correct’’ in silico docked conformation.
Despite the large differences in receptor stabilization induced
byMRL24 binding, it is just as good as rosiglitazone, if not better,
at blocking Cdk5-mediated phosphorylation of Ser245 in vitro
and in vivo (Choi et al., 2010). Our NMR data reveal that
MRL24 better stabilizes the b sheet region and the Ser245 site
compared to rosiglitazone, as inferred via relative NMR cross-
peak intensities for residues in these regions. Also in agreement
with our data showing that MRL20 is less efficacious than these
ligands in blocking Ser245 phosphorylation in vitro, our NMR
data reveal that MRL20 is less effective at stabilizing the b sheet
region and the Ser245 site. Furthermore, MRL20 and MRL24
both significantly and differentially impact the intermediate and
slow time scale dynamics of PPARg near the b sheet region,
H2, H20, and H7. These are regions that are near or involved in
a long-range contact between the PPARg LBD and the RXRa
DBD in the intact PPARg/RXRa structure (Chandra et al.,
2008). This observation, combined with our NMR observations
revealing that these ligands regulate the dynamics of this
surface, suggests a potential for long-range, ligand-mediated
dynamic allostery between RXRa DBD and PPARg LBD. How-
ever, a recent solution analysis using SAXS, SANS, and FRET
suggests this long-range interaction may be only stabilized by
a minor transient conformation (Rochel et al., 2011).
There is an apparent correlation between the relative receptor
NMR populations induced by ligand binding and the degree of
ligand-induced transactivation. For example, rosiglitazone stabi-
lizes PPARg Lys230 (Figure 3A) into one chemical shift popula-
tion (Paz1, Pbz0), whereas two populations are observed for–150, January 11, 2012 ª2012 Elsevier Ltd All rights reserved 147
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(Pa = 0.76, Pb = 0.24). Though the functional implications of the
relative populations Pa and Pb are not completely apparent,
generally the shift in population balance is associated with the
degree of agonism. Furthermore, our observation that MRL20
and MRL24 sample multiple binding modes suggests that
perhaps one binding mode may be more active in terms of clas-
sical transactivation. More apparent is the correlation between
the degree of H11/H12 stabilization on the intermediate time
scale and graded transactivation response. MRL20, which dis-
plays 60% transactivation compared to rosiglitazone, only in-
duces a partial stabilization of H11 and H12 compared to the
full stabilization afforded by rosiglitazone. The degree of stabili-
zation induced by MRL24 is even less, which is consistent with
its 25% transactivation response compared to rosiglitazone.
As noted before, these observations are inconsistent with
the single H12 conformation observed in the ligand-receptor
co-crystal structures (Bruning et al., 2007). The combination of
our NMR and HDX data support a model by which increased
conformational mobility of H12 negatively affects coregulator
interaction and transactivation (Bruning et al., 2007). Thus, the
‘‘active’’ conformation of H12 in the ligand-receptor co-crystal
structures may indeed represent a conformational ‘‘snapshot’’
of the receptor-coregulator interaction but is not fully represen-
tative of the receptor LBD conformation in solution.
There have been previous suggestions for a role of ligand
dynamics in the mechanism of graded agonism. The regioiso-
meric PPARg ligands studied, MRL20 and MRL24, crystallized
into two distinct conformations within the LBP of PPARg (Fig-
ure 1F) with binding modes associated with their respective
activity profiles (Bruning et al., 2007). However, we have shown
that the primary binding mode of one ligand (i.e., MRL20) is not
the secondary binding mode for the other (i.e., MRL24). Our
previous NMR study revealed that the PPARg partial agonist
nTZDpa induces a receptor conformation that is distinct from
and less stable than the receptor conformation when bound to
the full agonist rosiglitazone (Berger et al., 2003). An estrogen
receptor (ER) partial agonist, WAY-166916, differently bound to
the receptor when mutant proteins were used that stabilized
the active and inactive conformations (Bruning et al., 2010). In
this study, a series ofWAY-166916-derived ligandswere synthe-
sized that had graded transcriptional response profiles and
crystallized to the ER mutant proteins in a manner consistent
with their activity profiles. Interestingly, the authors state that
ligand-receptor co-crystal structures of ER partial agonists are
hard to obtain, requiring protein mutations to stabilize receptor
conformations. Indeed, this may arise because of the general
ability of NR partial agonists to bind in multiple binding modes
in a dynamic nature, as opposed to the more static nature
preferred for crystallization. This implies that ligand dynamics
is likely involved in the mechanism of partial NR agonism. In
terms of non-NR proteins, differences in binding modes for
similar compounds have been noted (Teague, 2003) in crystal
structures of transthyretin (Faig et al., 2001) and NAD(P)
H:Quinone Oxidoreductase 1 (Faig et al., 2001), where similar
ligands also display flipped binding modes. Technologically
related to our work, a ligand-detected NMR study revealed
that a single ligand can have multiple binding modes when
bound to riboflavin synthase, whereas another ligand that binds148 Structure 20, 139–150, January 11, 2012 ª2012 Elsevier Ltd All rthe same protein has only one binding mode (Scheuring et al.,
1996).
Our observations could have significant implications in the
future development of PPARg partial agonists, or ligands with
no agonism, which are highly sought after modulators because
they have potent insulin sensitizing activity but are anti-adipo-
genic with less propensity for edema, weight gain, and other
unwanted effects (Choi et al., 2011; Grether et al., 2010;
Houtkooper and Auwerx, 2010; Kahn and McGraw, 2010). Our
observations may also have implications for rational/structure-
based drug design, where it is generally assumed that ligands
have one binding mode, typically inferred via crystal structures
(Guasch et al., 2011), and differences in binding modes between
highly related ligands may be considered ‘‘surprising’’ (Teague,
2003). Future studies will determine if this is a general feature
for graded/partial receptor agonism in other systems, as well
as determine if selecting for ligands with a single binding mode
versus multiple binding modes can have impact on the desired
pharmacological response of the ligand. Lastly, our work shows
the great utility in combining multidisciplinary approaches, in-
cluding X-ray crystallography and HDX and NMR spectroscopy,
to provide detailed insight into mechanism of action of small
molecule ligands.
EXPERIMENTAL PROCEDURES
Protein Expression, Purification, and Sample Preparation
DNA encoding the PPARg (NR1C3) LBD (residues 205–477; UniProt ID
P37231, isoform 1) and RXRa (NR2B1) LBD (residues 223–462; UniProt ID
P19793) was amplified by PCR and cloned into the expression vector
pET-46 using the Ek/LIC system (EMD Chemicals/Novagen) as a tobacco
etch virus protease-cleavable N-terminal HisTag fusion protein. Expression
and purification details are described in the Supplementary Methods. The
rosiglitazone-bound sample was 1.0 mM; the MRL20, MRL24, and apo sam-
ples were 0.25 mM; in 20 mM potassium phosphate (pH 7.4), 50 mM potas-
sium chloride, 0.05% sodium azide (NMR buffer). A [2H,13C,15N]-PPARg/
unlabeled-RXRa LBD (RXRa complexed to 9-cis-retinoic acid) heterodimer
sample was prepared from the NMR sample of [2H,13C,15N]-PPARg LBD
bound to MRL24. For the ligand-observe experiments, 1H experiments were
performed on the aforementioned ligand-bound receptor samples; ligand-
only samples were at 50 mM in NMR buffer at 0.5% DMSO; and other unla-
beled-receptor ligand experiments contained 200–500 mM protein. Ligands
were added in 1.35 to 2-fold molar excess to approximately 10 mM protein
and then buffer exchanged and/or concentrated.
NMR Spectroscopy
NMR data were collected at 25C on a Bruker spectrometer at 700 MHz 1H
frequency equipped with a TXI probe and Varian spectrometers at 600 and
800 MHz 1H frequency with a conventional (600 MHz) or cryogenically cooled
(800 MHz) triple-resonance probe. The proton carrier frequency was set coin-
cident with the water resonance for all experiments. Backbone assignments
for the PPARg LBD bound to rosiglitazone (1.0 mM protein), MRL24 (250 mM
protein), and MRL20 (250 mM protein) were obtained using 3D TROSY-based
assignment experiments available in Varian VNMRJ/BioPack or Bruker
Topspin, including HNCO, HNCA, HN(CO)CA, HN(CA)CB, and HN(COCA)
CB, as well as 15N-NOESY-HSQC or 15N-NOESY-TROSY-HSQC (tmix =
120 ms), using [2H,13C,15N]-labeled protein. Two-dimensional [1H-15N]-
TROSY-HSQC and 3D HNCO data were collected on apo/ligand-free
[13C,15N]-Histag-PPARg LBD. Data were processed with NMRPipe (Delaglio
et al., 1995) and analyzed with NMRViewJ (Johnson, 2004; One Moon Scien-
tific, Inc.). Backbone chemical shift assignments were obtained for 245, 186,
and 170 out of 264 nonproline PPARg LBD residues in the presence of rosigli-
tazone (93%), MRL24 (70%), and MRL20 (64%), respectively. Chemical shift
assignments for the PPARg LBD complexed to rosiglitazone, MRL24 andights reserved
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bmrb.wisc.edu) under accession codes 17975, 17976, and 17977, respec-
tively. ZZ-exchange spectroscopy (EXSY) was used to attempt to quantify
the rate of slow exchange (Farrow et al., 1994) using relaxation delays ranging
from 5 to 900 ms. The heterodimer sample concentration was estimated to
be 75–100 mM and had relative decrease of 75% in 1D 1H NMR signal
compared to the [2H,13C,15N]-PPARg sample bound to MRL24.
Ligand-detected NMR was performed using 1D 19F and 1D 1H NMR exper-
iments, including a 19F NMR experiment without 1H decoupling at 659 MHz
(free and receptor-bound ligand), a 1D 1H NMR experiment with water
suppression (Hwang and Shaka, 1995) at 700 MHz (free ligand), and
a [13C,15N]-isotope-filtered experiment with water suppression (Ikura and
Bax, 1992) at 700 MHz (ligand bound to [2H,13C,15N]-PPARg LBD). Protein-
ligand complex concentrations ranged from 200–500 mM. In the case of the
receptor-bound ligand NMR data, which reveals the ligand is in slow exchange
between multiple conformations, specific assignment of the receptor-bound
ligand protons was complicated as NMR spin coupling patterns are not well
resolved due to the slower ligand correlation time which is comparable to
that of the receptor and not to free ligand. Receptor-bound chemical shift
assignments weremapped using the relative peak intensity profiles and chem-
ical shift values for groups 1, 3, and 4, leaving peaks for group 2, which does
not strictly follow the same intensity profile as free ligand perhaps due to chem-
ical shift line broadening. Data were processed and analyzed using dataChord
Spectrum Analyst (One Moon Scientific, Inc.).
Ligands
Rosiglitazone was obtained commercially (Cayman Chemical). MRL20 and
MRL24were synthesized in-house using previously describedmethods (Acton
et al., 2005).
HDX-MS
Solution phase amide HDX was performed on liganded and unliganded
PPARg LBD using a fully automated system and in-house software described
previously (Chalmers et al., 2006; Chalmers et al., 2011; Pascal et al., 2009).
Changes reported in HDX are from direct comparisons between unliganded
and liganded PPARg LBD. Details are described in the Supplemental
Methods.
Ligand Docking
AutoDock Vina (Trott and Olson, 2010) was used for molecular docking studies
of MRL20 and MRL24 to their respective crystal structures (Bruning et al.,
2007) using standard parameters, except for the degree of exhaustiveness
(=30). The search space comprised the entire LBP of the PPARg LBD. The
ligandoccupancy of the various stateswas calculated (1) assuming a canonical
ensemble in which the number of molecules, the volume, and the temperature
are fixed; and (2) all states were considered equally degenerate. The fraction of
the total ligands occupying a docked state and energy was calculated using
the canonical Boltzmann distribution:
eðεiε0Þ=kBT
P
i
eðεiε0Þ=kBT
;
where εo is the energy of the lowest energy level of the predicted ligand confor-
mation, εi is the energy of the other energy levels, kB is the Boltzman constant,
T is the temperature, and the denominator is the sum of all the probabilities of
the states analyzed for each ligand.
Cell-Based Reporter Assay
293T cells were cotransfected in batch by adding 4.5 mg each of full-length
Gal4-PPARg andUAS-luciferase reporter using 27 ml X-tremeGene 9 transfec-
tion reagent (Roche) in Opti-mem reduced serum media (GIBCO). Cells were
plated at a density of 4x106 in 100x20mm polystyrene dishes (BD Falcon)
with DMEM containing 10% FBS. Following 18 hr incubation at 37C, 5%
CO2, transfected cells were plated in triplicate in white 384-well plates (Perkin
Elmer) at a density of 10,000 cells/well. Cells were treated with either 0.1%
DMSO vehicle or compound MRL-20, MRL-24, or Rosiglitazone in increasing
doses from 333 pM-10 mM for 18 hr. The luciferase was quantitated with 20 ml
Brite Lite Plus (Perkin Elmer) and read in 384-well Luminescence Perkin ElmerStructure 20, 139EnVision Multilabel plate reader. Graphs were plotted in GraphPad Prism
Software as fold change of treated cells over DMSO control cells.
In Vitro Cdk5/p35 Kinase Biochemical Assay
In vitro Cdk5 kinase assay was performed as previously described (Choi et al.,
2010). Briefly, active Cdk5/p35 kinase was purchased fromMillipore. 0.5mg of
purified WT PPARg was incubated with 0.25 mg active Cdk5 in kinase assay
buffer (25 mM Tris-HCl pH 7.5, 5 mM b-glycerophosphate, 2 mM dithiothreitol
(DTT), and 0.1 mM Na3VO4, 10 mM MgCl2) for 2 hr at 30
C. Twenty mM ATP
was added to complex for 15 min at 30C. PPARg ligands were pre-incubated
with receptor for 1 hr prior to addition of ATP and the assay was performed.
Phosphorylation of substrates after SDS–PAGE was analyzed with an anti-
phospho Ser245 (Ser273 in PPARg2) polyclonal antibody. Densitometry anal-
ysis using ImageJ (NIH) was used to determine the relative efficacies for the
ligands in blocking phosphorylation of Ser245.
Structural Nomenclature and Analysis
The sequence and secondary structure nomenclauture for the PPARg LBD has
been described previously (Uppenberg et al., 1998). Secondary structure
nomenclature: helix is abbreviated as ‘‘H’’; b strand as ‘‘b’’; and loop as ‘‘L’’
with numbers corresponding to the helix preceding and following the loop.
PyMOL was used for structural visualization (DeLano Scientific, South San
Francisco, CA), and THESEUS (Theobald and Wuttke, 2006, 2008) was used
for principal component analysis of PPARg ligand-bound structures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes one table, four figures and Supplemental
Experimental Procedures and can be found with this article online at doi:10.
1016/j.str.2011.10.018.
ACKNOWLEDGMENTS
We are grateful for support from B. Pascal and S. Willis for software analyzing
the HDX data. This work was supported in part by James and Esther King
Biomedical Research Program, Florida Department of Health (1KN-09 to
D.J.K.), start-up funds from The Scripps Research Institute (to D.J.K.), the
U.S. National Institutes of Health (NIH) National Institute of General Medical
Sciences (R01-GM084041 to P.R.G.; R01-GM063855 to M.R.), and the
National Center for Research Resources (RR19077 and RR027755 to M.R.).
Received: August 30, 2011
Revised: October 6, 2011
Accepted: October 7, 2011
Published: January 10, 2012
REFERENCES
Acton, J.J., 3rd, Black, R.M., Jones, A.B., Moller, D.E., Colwell, L., Doebber,
T.W., Macnaul, K.L., Berger, J., and Wood, H.B. (2005). Benzoyl 2-methyl
indoles as selective PPARgamma modulators. Bioorg. Med. Chem. Lett. 15,
357–362.
Berger, J.P., Petro, A.E., Macnaul, K.L., Kelly, L.J., Zhang, B.B., Richards, K.,
Elbrecht, A., Johnson, B.A., Zhou, G., Doebber, T.W., et al. (2003). Distinct
properties and advantages of a novel peroxisome proliferator-activated
protein [gamma] selective modulator. Mol. Endocrinol. 17, 662–676.
Bosco, D.A., Eisenmesser, E.Z., Pochapsky, S., Sundquist, W.I., and Kern, D.
(2002). Catalysis of cis/trans isomerization in native HIV-1 capsid by human
cyclophilin A. Proc. Natl. Acad. Sci. USA 99, 5247–5252.
Bru¨nger, A.T. (1997). X-ray crystallography and NMR reveal complementary
views of structure and dynamics. Nat. Struct. Biol. Suppl. 4, 862–865.
Bruning, J.B., Chalmers, M.J., Prasad, S., Busby, S.A., Kamenecka, T.M., He,
Y., Nettles, K.W., and Griffin, P.R. (2007). Partial agonists activate
PPARgamma using a helix 12 independent mechanism. Structure 15, 1258–
1271.
Bruning, J.B., Parent, A.A., Gil, G., Zhao, M., Nowak, J., Pace, M.C., Smith,
C.L., Afonine, P.V., Adams, P.D., Katzenellenbogen, J.A., and Nettles, K.W.–150, January 11, 2012 ª2012 Elsevier Ltd All rights reserved 149
Structure
Role of Dynamics in Graded PPARg Agonism(2010). Coupling of receptor conformation and ligand orientation determine
graded activity. Nat. Chem. Biol. 6, 837–843.
Chalmers, M.J., Busby, S.A., Pascal, B.D., He, Y., Hendrickson, C.L.,Marshall,
A.G., and Griffin, P.R. (2006). Probing protein ligand interactions by automated
hydrogen/deuterium exchange mass spectrometry. Anal. Chem. 78, 1005–
1014.
Chalmers, M.J., Pascal, B.D., Willis, S., Zhang, J., Iturria, S.J., Dodge, J.A.,
and Griffin, P.R. (2011). Methods for the Analysis of High Precision
Differential Hydrogen Deuterium Exchange Data. Int. J. Mass Spectrom.
302, 59–68.
Chandra, V., Huang, P., Hamuro, Y., Raghuram, S., Wang, Y., Burris, T.P., and
Rastinejad, F. (2008). Structure of the intact PPAR-gamma-RXR- nuclear
receptor complex on DNA. Nature 456, 350–356.
Choi, J.H., Banks, A.S., Estall, J.L., Kajimura, S., Bostro¨m, P., Laznik, D., Ruas,
J.L., Chalmers, M.J., Kamenecka, T.M., Blu¨her, M., et al. (2010). Anti-diabetic
drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5. Nature
466, 451–456.
Choi, J.H., Banks, A.S., Kamenecka, T.M., Busby, S.A., Chalmers, M.J.,
Kumar, N., Kuruvilla, D.S., Shin, Y., He, Y., Bruning, J.B., et al. (2011).
Antidiabetic actions of a non-agonist PPARg ligand blocking Cdk5-mediated
phosphorylation. Nature 477, 477–481.
Dai, S.Y., Chalmers, M.J., Bruning, J., Bramlett, K.S., Osborne, H.E.,
Montrose-Rafizadeh, C., Barr, R.J., Wang, Y., Wang, M., Burris, T.P., et al.
(2008). Prediction of the tissue-specificity of selective estrogen receptor
modulators by using a single biochemical method. Proc. Natl. Acad. Sci.
USA 105, 7171–7176.
Dai, S.Y., Burris, T.P., Dodge, J.A., Montrose-Rafizadeh, C., Wang, Y., Pascal,
B.D., Chalmers, M.J., and Griffin, P.R. (2009). Unique ligand binding patterns
between estrogen receptor alpha and beta revealed by hydrogen-deuterium
exchange. Biochemistry 48, 9668–9676.
Delaglio, F., Grzesiek, S., Vuister, G.W., Zhu, G., Pfeifer, J., and Bax, A. (1995).
NMRPipe: a multidimensional spectral processing system based on UNIX
pipes. J. Biomol. NMR 6, 277–293.
Faig, M., Bianchet, M.A., Winski, S., Hargreaves, R., Moody, C.J., Hudnott,
A.R., Ross, D., and Amzel, L.M. (2001). Structure-based development of anti-
cancer drugs: complexes of NAD(P)H:quinone oxidoreductase 1 with chemo-
therapeutic quinones. Structure 9, 659–667.
Farrow, N.A., Zhang, O., Forman-Kay, J.D., and Kay, L.E. (1994). A heteronu-
clear correlation experiment for simultaneous determination of 15N longitudinal
decay and chemical exchange rates of systems in slow equilibrium. J. Biomol.
NMR 4, 727–734.
Germain, P., Staels, B., Dacquet, C., Spedding, M., and Laudet, V. (2006).
Overview of nomenclature of nuclear receptors. Pharmacol. Rev. 58, 685–704.
Grether, U., Klaus, W., Kuhn, B., Maerki, H.P., Mohr, P., and Wright, M.B.
(2010). New Insights on the mechanism of PPAR-targeted drugs.
ChemMedChem 5, 1973–1976.
Guasch, L., Sala, E., Valls, C., Blay, M., Mulero, M., Arola, L., Pujadas, G., and
Garcia-Vallve, S. (2011). Structural insights for the design of new PPARgamma
partial agonists with high binding affinity and low transactivation activity.
J. Comput. Aided Mol. Des. 25, 717–728.
Hamuro, Y., Coales, S.J., Morrow, J.A., Molnar, K.S., Tuske, S.J., Southern,
M.R., and Griffin, P.R. (2006). Hydrogen/deuterium-exchange (H/D-Ex) of
PPARgamma LBD in the presence of various modulators. Protein Sci. 15,
1883–1892.
Heldring, N., Pike, A., Andersson, S., Matthews, J., Cheng, G., Hartman, J.,
Tujague, M., Stro¨m, A., Treuter, E., Warner, M., and Gustafsson, J.A. (2007).
Estrogen receptors: how do they signal and what are their targets. Physiol.
Rev. 87, 905–931.
Henzler-Wildman, K., and Kern, D. (2007). Dynamic personalities of proteins.
Nature 450, 964–972.
Houtkooper, R.H., and Auwerx, J. (2010). Obesity: New life for antidiabetic
drugs. Nature 466, 443–444.150 Structure 20, 139–150, January 11, 2012 ª2012 Elsevier Ltd All rHwang, T.-L., and Shaka, A.J. (1995). Water Suppression That Works.
Excitation Sculpting Using Arbitrary Waveforms and Pulse Field Gradients.
J. Magn. Reson. A 112, 275–279.
Ikura, M., and Bax, A. (1992). Isotope-filtered 2D NMR of a protein-peptide
complex: study of a skeletal muscle myosin light chain kinase fragment bound
to calmodulin. J. Am. Chem. Soc. 114, 2433–2440.
Johnson, B.A. (2004). Using NMRView to visualize and analyze the NMR
spectra of macromolecules. Methods Mol. Biol. 278, 313–352.
Johnson, B.A., Wilson, E.M., Li, Y., Moller, D.E., Smith, R.G., and Zhou, G.
(2000). Ligand-induced stabilization of PPARgamma monitored by NMR
spectroscopy: implications for nuclear receptor activation. J. Mol. Biol. 298,
187–194.
Kahn, B.B., and McGraw, T.E. (2010). Rosiglitazone, PPARg, and type 2
diabetes. N. Engl. J. Med. 363, 2667–2669.
Kleckner, I.R., and Foster, M.P. (2011). An introduction to NMR-based
approaches for measuring protein dynamics. Biochim. Biophys. Acta 1814,
942–968.
Lu, J., Chen, M., Stanley, S.E., and Li, E. (2008). Effect of heterodimer partner
RXRalpha on PPARgamma activation function-2 helix in solution. Biochem.
Biophys. Res. Commun. 365, 42–46.
Mauldin, R.V., Carroll, M.J., and Lee, A.L. (2009). Dynamic dysfunction in dihy-
drofolate reductase results from antifolate drug binding: modulation of
dynamics within a structural state. Structure 17, 386–394.
Moore, J.T., Collins, J.L., and Pearce, K.H. (2006). The nuclear receptor super-
family and drug discovery. ChemMedChem 1, 504–523.
Pascal, B.D., Chalmers, M.J., Busby, S.A., and Griffin, P.R. (2009). HD
desktop: an integrated platform for the analysis and visualization of H/D
exchange data. J. Am. Soc. Mass Spectrom. 20, 601–610.
Peng, J.W. (2009). Communication breakdown: protein dynamics and drug
design. Structure 17, 319–320.
Rochel, N., Ciesielski, F., Godet, J., Moman, E., Roessle, M., Peluso-Iltis, C.,
Moulin, M., Haertlein, M., Callow, P., Me´ly, Y., et al. (2011). Common architec-
ture of nuclear receptor heterodimers on DNA direct repeat elements with
different spacings. Nat. Struct. Mol. Biol. 18, 564–570.
Scheuring, J., Fischer, M., Cushman,M., Lee, J., Bacher, A., andOschkinat, H.
(1996). NMR analysis of site-specific ligand binding in oligomeric proteins.
Dynamic studies on the interaction of riboflavin synthase with trifluoro-
methyl-substituted intermediates. Biochemistry 35, 9637–9646.
Sheu, S.H., Kaya, T.,Waxman, D.J., and Vajda, S. (2005). Exploring the binding
site structure of the PPAR gamma ligand-binding domain by computational
solvent mapping. Biochemistry 44, 1193–1209.
Teague, S.J. (2003). Implications of protein flexibility for drug discovery. Nat.
Rev. Drug Discov. 2, 527–541.
Theobald, D.L., and Wuttke, D.S. (2006). THESEUS: maximum likelihood
superpositioning and analysis of macromolecular structures. Bioinformatics
22, 2171–2172.
Theobald, D.L., and Wuttke, D.S. (2008). Accurate structural correlations from
maximum likelihood superpositions. PLoS Comput. Biol. 4, e43.
Trott, O., and Olson, A.J. (2010). AutoDock Vina: improving the speed and
accuracy of docking with a new scoring function, efficient optimization, and
multithreading. J. Comput. Chem. 31, 455–461.
Uppenberg, J., Svensson, C., Jaki, M., Bertilsson, G., Jendeberg, L., and
Berkenstam, A. (1998). Crystal structure of the ligand binding domain of the
human nuclear receptor PPARgamma. J. Biol. Chem. 273, 31108–31112.
Zhang, J., Chalmers, M.J., Stayrook, K.R., Burris, L.L., Garcia-Ordonez, R.D.,
Pascal, B.D., Burris, T.P., Dodge, J.A., and Griffin, P.R. (2010). Hydrogen/
deuterium exchange reveals distinct agonist/partial agonist receptor dynamics
within vitamin D receptor/retinoid X receptor heterodimer. Structure 18, 1332–
1341.ights reserved
